Two years after flop, Verona gets a win as it preps for pivotal Phase III trials
Two years after the lead formulation of Verona’s lead COPD drug whiffed in a Phase II study that knocked back their stock, another formulation has hit across the board.
Verona said Tuesday that all four doses of an inhaler form of its compound ensifentrine significantly improved lung function in a 40-person Phase II trial of the chronic condition. Most doses of the drug hit on all primary and secondary endpoints, with the effect increasing with the dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.